 | • レポートコード：MRC2-11QY03648 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は癌治療用モノクローナル抗体のグローバル市場について調査・分析したレポートです。種類別（マウス抗体、キメラ・ヒト化抗体、完全ヒト化抗体、その他）市場規模、用途別（肝臓、乳房、血液、脳、ホジキンリンパ腫・非ホジキンリンパ腫、結腸直腸、白血病、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別癌治療用モノクローナル抗体の競争状況、市場シェア ・世界の癌治療用モノクローナル抗体市場：種類別市場規模 2015年-2020年（マウス抗体、キメラ・ヒト化抗体、完全ヒト化抗体、その他） ・世界の癌治療用モノクローナル抗体市場：種類別市場規模予測 2021年-2026年（マウス抗体、キメラ・ヒト化抗体、完全ヒト化抗体、その他） ・世界の癌治療用モノクローナル抗体市場：用途別市場規模 2015年-2020年（肝臓、乳房、血液、脳、ホジキンリンパ腫・非ホジキンリンパ腫、結腸直腸、白血病、その他） ・世界の癌治療用モノクローナル抗体市場：用途別市場規模予測 2021年-2026年（肝臓、乳房、血液、脳、ホジキンリンパ腫・非ホジキンリンパ腫、結腸直腸、白血病、その他） ・北米の癌治療用モノクローナル抗体市場分析：米国、カナダ ・ヨーロッパの癌治療用モノクローナル抗体市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの癌治療用モノクローナル抗体市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の癌治療用モノクローナル抗体市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの癌治療用モノクローナル抗体市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：F. Hoffmann-La Roche、Amgen、Bristol-Myers Squibb、Takeda Pharmaceuticals ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
The mAbs, which are produced by genetic engineering, target antigens in cells, tissues, and organs. They are used in clinical applications to treat diseases with excellent efficacy and minimal side effects. Their MOA, absence of generic pathway, and therapeutic applications distinguish them from other targeted therapeutics.
Cancer is one of the leading causes of death globally. There were 10.9 million new cases, in 2002, which increased to 14.1 million, in 2012 (approximately 30% growth in a decade). The WHO expects this number to increase by 70%, over the next two decades. According to the WHO, almost 70% of deaths occur in low and middle-income countries. The increment in data is expected to provide the basis for any national policy on cancer, leading to an increase in the percentage of people choosing cancer treatment. In the healthcare sector, cancer is one of the biggest concerns. Thus, the increased use of monoclonal antibodies for the treatment of cancer is driving this market.
Market Analysis and Insights: Global Cancer Monoclonal Antibodies Market
The global Cancer Monoclonal Antibodies market size is projected to reach US$ 37710 million by 2026, from US$ 34310 million in 2020, at a CAGR of 9.2%% during 2021-2026.
Global Cancer Monoclonal Antibodies Scope and Market Size
Cancer Monoclonal Antibodies market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Cancer Monoclonal Antibodies market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Cancer Monoclonal Antibodies market is segmented into
Murine Antibodies
Chimeric and Humanised Antibodies
Fully Humanized Antibodies
Others
Segment by Application, the Cancer Monoclonal Antibodies market is segmented into
Liver
Breast
Blood
Brain
Hodgkins and Non-Hodgkins lymphoma
Colorectal
Leukaemia
Others
Regional and Country-level Analysis
The Cancer Monoclonal Antibodies market is analysed and market size information is provided by regions (countries).
The key regions covered in the Cancer Monoclonal Antibodies market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Cancer Monoclonal Antibodies Market Share Analysis
Cancer Monoclonal Antibodies market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Cancer Monoclonal Antibodies business, the date to enter into the Cancer Monoclonal Antibodies market, Cancer Monoclonal Antibodies product introduction, recent developments, etc.
The major vendors covered:
F. Hoffmann-La Roche
Amgen
Bristol-Myers Squibb
Takeda Pharmaceuticals
…
1 Study Coverage
1.1 Cancer Monoclonal Antibodies Product Introduction
1.2 Market Segments
1.3 Key Cancer Monoclonal Antibodies Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Cancer Monoclonal Antibodies Market Size Growth Rate by Type
1.4.2 Murine Antibodies
1.4.3 Chimeric and Humanised Antibodies
1.4.4 Fully Humanized Antibodies
1.4.5 Others
1.5 Market by Application
1.5.1 Global Cancer Monoclonal Antibodies Market Size Growth Rate by Application
1.5.2 Liver
1.5.3 Breast
1.5.4 Blood
1.5.5 Brain
1.5.6 Hodgkins and Non-Hodgkins lymphoma
1.5.7 Colorectal
1.5.8 Leukaemia
1.5.9 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Cancer Monoclonal Antibodies Market Size, Estimates and Forecasts
2.1.1 Global Cancer Monoclonal Antibodies Revenue 2015-2026
2.1.2 Global Cancer Monoclonal Antibodies Sales 2015-2026
2.2 Global Cancer Monoclonal Antibodies, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Cancer Monoclonal Antibodies Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Cancer Monoclonal Antibodies Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Cancer Monoclonal Antibodies Competitor Landscape by Players
3.1 Cancer Monoclonal Antibodies Sales by Manufacturers
3.1.1 Cancer Monoclonal Antibodies Sales by Manufacturers (2015-2020)
3.1.2 Cancer Monoclonal Antibodies Sales Market Share by Manufacturers (2015-2020)
3.2 Cancer Monoclonal Antibodies Revenue by Manufacturers
3.2.1 Cancer Monoclonal Antibodies Revenue by Manufacturers (2015-2020)
3.2.2 Cancer Monoclonal Antibodies Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Cancer Monoclonal Antibodies Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Cancer Monoclonal Antibodies Revenue in 2019
3.2.5 Global Cancer Monoclonal Antibodies Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Cancer Monoclonal Antibodies Price by Manufacturers
3.4 Cancer Monoclonal Antibodies Manufacturing Base Distribution, Product Types
3.4.1 Cancer Monoclonal Antibodies Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Cancer Monoclonal Antibodies Product Type
3.4.3 Date of International Manufacturers Enter into Cancer Monoclonal Antibodies Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Cancer Monoclonal Antibodies Market Size by Type (2015-2020)
4.1.1 Global Cancer Monoclonal Antibodies Sales by Type (2015-2020)
4.1.2 Global Cancer Monoclonal Antibodies Revenue by Type (2015-2020)
4.1.3 Cancer Monoclonal Antibodies Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Cancer Monoclonal Antibodies Market Size Forecast by Type (2021-2026)
4.2.1 Global Cancer Monoclonal Antibodies Sales Forecast by Type (2021-2026)
4.2.2 Global Cancer Monoclonal Antibodies Revenue Forecast by Type (2021-2026)
4.2.3 Cancer Monoclonal Antibodies Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Cancer Monoclonal Antibodies Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Cancer Monoclonal Antibodies Market Size by Application (2015-2020)
5.1.1 Global Cancer Monoclonal Antibodies Sales by Application (2015-2020)
5.1.2 Global Cancer Monoclonal Antibodies Revenue by Application (2015-2020)
5.1.3 Cancer Monoclonal Antibodies Price by Application (2015-2020)
5.2 Cancer Monoclonal Antibodies Market Size Forecast by Application (2021-2026)
5.2.1 Global Cancer Monoclonal Antibodies Sales Forecast by Application (2021-2026)
5.2.2 Global Cancer Monoclonal Antibodies Revenue Forecast by Application (2021-2026)
5.2.3 Global Cancer Monoclonal Antibodies Price Forecast by Application (2021-2026)
6 North America
6.1 North America Cancer Monoclonal Antibodies by Country
6.1.1 North America Cancer Monoclonal Antibodies Sales by Country
6.1.2 North America Cancer Monoclonal Antibodies Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Cancer Monoclonal Antibodies Market Facts & Figures by Type
6.3 North America Cancer Monoclonal Antibodies Market Facts & Figures by Application
7 Europe
7.1 Europe Cancer Monoclonal Antibodies by Country
7.1.1 Europe Cancer Monoclonal Antibodies Sales by Country
7.1.2 Europe Cancer Monoclonal Antibodies Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Cancer Monoclonal Antibodies Market Facts & Figures by Type
7.3 Europe Cancer Monoclonal Antibodies Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Cancer Monoclonal Antibodies by Region
8.1.1 Asia Pacific Cancer Monoclonal Antibodies Sales by Region
8.1.2 Asia Pacific Cancer Monoclonal Antibodies Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Cancer Monoclonal Antibodies Market Facts & Figures by Type
8.3 Asia Pacific Cancer Monoclonal Antibodies Market Facts & Figures by Application
9 Latin America
9.1 Latin America Cancer Monoclonal Antibodies by Country
9.1.1 Latin America Cancer Monoclonal Antibodies Sales by Country
9.1.2 Latin America Cancer Monoclonal Antibodies Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Cancer Monoclonal Antibodies Market Facts & Figures by Type
9.3 Central & South America Cancer Monoclonal Antibodies Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Cancer Monoclonal Antibodies by Country
10.1.1 Middle East and Africa Cancer Monoclonal Antibodies Sales by Country
10.1.2 Middle East and Africa Cancer Monoclonal Antibodies Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Cancer Monoclonal Antibodies Market Facts & Figures by Type
10.3 Middle East and Africa Cancer Monoclonal Antibodies Market Facts & Figures by Application
11 Company Profiles
11.1 F. Hoffmann-La Roche
11.1.1 F. Hoffmann-La Roche Corporation Information
11.1.2 F. Hoffmann-La Roche Description and Business Overview
11.1.3 F. Hoffmann-La Roche Sales, Revenue and Gross Margin (2015-2020)
11.1.4 F. Hoffmann-La Roche Cancer Monoclonal Antibodies Products Offered
11.1.5 F. Hoffmann-La Roche Related Developments
11.2 Amgen
11.2.1 Amgen Corporation Information
11.2.2 Amgen Description and Business Overview
11.2.3 Amgen Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Amgen Cancer Monoclonal Antibodies Products Offered
11.2.5 Amgen Related Developments
11.3 Bristol-Myers Squibb
11.3.1 Bristol-Myers Squibb Corporation Information
11.3.2 Bristol-Myers Squibb Description and Business Overview
11.3.3 Bristol-Myers Squibb Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Bristol-Myers Squibb Cancer Monoclonal Antibodies Products Offered
11.3.5 Bristol-Myers Squibb Related Developments
11.4 Takeda Pharmaceuticals
11.4.1 Takeda Pharmaceuticals Corporation Information
11.4.2 Takeda Pharmaceuticals Description and Business Overview
11.4.3 Takeda Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Takeda Pharmaceuticals Cancer Monoclonal Antibodies Products Offered
11.4.5 Takeda Pharmaceuticals Related Developments
11.1 F. Hoffmann-La Roche
11.1.1 F. Hoffmann-La Roche Corporation Information
11.1.2 F. Hoffmann-La Roche Description and Business Overview
11.1.3 F. Hoffmann-La Roche Sales, Revenue and Gross Margin (2015-2020)
11.1.4 F. Hoffmann-La Roche Cancer Monoclonal Antibodies Products Offered
11.1.5 F. Hoffmann-La Roche Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Cancer Monoclonal Antibodies Market Estimates and Projections by Region
12.1.1 Global Cancer Monoclonal Antibodies Sales Forecast by Regions 2021-2026
12.1.2 Global Cancer Monoclonal Antibodies Revenue Forecast by Regions 2021-2026
12.2 North America Cancer Monoclonal Antibodies Market Size Forecast (2021-2026)
12.2.1 North America: Cancer Monoclonal Antibodies Sales Forecast (2021-2026)
12.2.2 North America: Cancer Monoclonal Antibodies Revenue Forecast (2021-2026)
12.2.3 North America: Cancer Monoclonal Antibodies Market Size Forecast by Country (2021-2026)
12.3 Europe Cancer Monoclonal Antibodies Market Size Forecast (2021-2026)
12.3.1 Europe: Cancer Monoclonal Antibodies Sales Forecast (2021-2026)
12.3.2 Europe: Cancer Monoclonal Antibodies Revenue Forecast (2021-2026)
12.3.3 Europe: Cancer Monoclonal Antibodies Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Cancer Monoclonal Antibodies Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Cancer Monoclonal Antibodies Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Cancer Monoclonal Antibodies Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Cancer Monoclonal Antibodies Market Size Forecast by Region (2021-2026)
12.5 Latin America Cancer Monoclonal Antibodies Market Size Forecast (2021-2026)
12.5.1 Latin America: Cancer Monoclonal Antibodies Sales Forecast (2021-2026)
12.5.2 Latin America: Cancer Monoclonal Antibodies Revenue Forecast (2021-2026)
12.5.3 Latin America: Cancer Monoclonal Antibodies Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Cancer Monoclonal Antibodies Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Cancer Monoclonal Antibodies Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Cancer Monoclonal Antibodies Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Cancer Monoclonal Antibodies Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Cancer Monoclonal Antibodies Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Cancer Monoclonal Antibodies Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Cancer Monoclonal Antibodies Market Segments
Table 2. Ranking of Global Top Cancer Monoclonal Antibodies Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Cancer Monoclonal Antibodies Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million)
Table 4. Major Manufacturers of Murine Antibodies
Table 5. Major Manufacturers of Chimeric and Humanised Antibodies
Table 6. Major Manufacturers of Fully Humanized Antibodies
Table 7. Major Manufacturers of Others
Table 8. Global Cancer Monoclonal Antibodies Market Size Growth Rate by Application 2020-2026 (K Units)
Table 9. Global Cancer Monoclonal Antibodies Market Size by Region (K Units) & (US$ Million): 2020 VS 2026
Table 10. Global Cancer Monoclonal Antibodies Sales by Regions 2015-2020 (K Units)
Table 11. Global Cancer Monoclonal Antibodies Sales Market Share by Regions (2015-2020)
Table 12. Global Cancer Monoclonal Antibodies Revenue by Regions 2015-2020 (US$ Million)
Table 13. Global Cancer Monoclonal Antibodies Sales by Manufacturers (2015-2020) (K Units)
Table 14. Global Cancer Monoclonal Antibodies Sales Share by Manufacturers (2015-2020)
Table 15. Global Cancer Monoclonal Antibodies Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 16. Global Cancer Monoclonal Antibodies by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Cancer Monoclonal Antibodies as of 2019)
Table 17. Cancer Monoclonal Antibodies Revenue by Manufacturers (2015-2020) (US$ Million)
Table 18. Cancer Monoclonal Antibodies Revenue Share by Manufacturers (2015-2020)
Table 19. Key Manufacturers Cancer Monoclonal Antibodies Price (2015-2020) (USD/Unit)
Table 20. Cancer Monoclonal Antibodies Manufacturers Manufacturing Base Distribution and Headquarters
Table 21. Manufacturers Cancer Monoclonal Antibodies Product Type
Table 22. Date of International Manufacturers Enter into Cancer Monoclonal Antibodies Market
Table 23. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 24. Global Cancer Monoclonal Antibodies Sales by Type (2015-2020) (K Units)
Table 25. Global Cancer Monoclonal Antibodies Sales Share by Type (2015-2020)
Table 26. Global Cancer Monoclonal Antibodies Revenue by Type (2015-2020) (US$ Million)
Table 27. Global Cancer Monoclonal Antibodies Revenue Share by Type (2015-2020)
Table 28. Cancer Monoclonal Antibodies Average Selling Price (ASP) by Type 2015-2020 (USD/Unit)
Table 29. Global Cancer Monoclonal Antibodies Sales by Application (2015-2020) (K Units)
Table 30. Global Cancer Monoclonal Antibodies Sales Share by Application (2015-2020)
Table 31. North America Cancer Monoclonal Antibodies Sales by Country (2015-2020) (K Units)
Table 32. North America Cancer Monoclonal Antibodies Sales Market Share by Country (2015-2020)
Table 33. North America Cancer Monoclonal Antibodies Revenue by Country (2015-2020) (US$ Million)
Table 34. North America Cancer Monoclonal Antibodies Revenue Market Share by Country (2015-2020)
Table 35. North America Cancer Monoclonal Antibodies Sales by Type (2015-2020) (K Units)
Table 36. North America Cancer Monoclonal Antibodies Sales Market Share by Type (2015-2020)
Table 37. North America Cancer Monoclonal Antibodies Sales by Application (2015-2020) (K Units)
Table 38. North America Cancer Monoclonal Antibodies Sales Market Share by Application (2015-2020)
Table 39. Europe Cancer Monoclonal Antibodies Sales by Country (2015-2020) (K Units)
Table 40. Europe Cancer Monoclonal Antibodies Sales Market Share by Country (2015-2020)
Table 41. Europe Cancer Monoclonal Antibodies Revenue by Country (2015-2020) (US$ Million)
Table 42. Europe Cancer Monoclonal Antibodies Revenue Market Share by Country (2015-2020)
Table 43. Europe Cancer Monoclonal Antibodies Sales by Type (2015-2020) (K Units)
Table 44. Europe Cancer Monoclonal Antibodies Sales Market Share by Type (2015-2020)
Table 45. Europe Cancer Monoclonal Antibodies Sales by Application (2015-2020) (K Units)
Table 46. Europe Cancer Monoclonal Antibodies Sales Market Share by Application (2015-2020)
Table 47. Asia Pacific Cancer Monoclonal Antibodies Sales by Region (2015-2020) (K Units)
Table 48. Asia Pacific Cancer Monoclonal Antibodies Sales Market Share by Region (2015-2020)
Table 49. Asia Pacific Cancer Monoclonal Antibodies Revenue by Region (2015-2020) (US$ Million)
Table 50. Asia Pacific Cancer Monoclonal Antibodies Revenue Market Share by Region (2015-2020)
Table 51. Asia Pacific Cancer Monoclonal Antibodies Sales by Type (2015-2020) (K Units)
Table 52. Asia Pacific Cancer Monoclonal Antibodies Sales Market Share by Type (2015-2020)
Table 53. Asia Pacific Cancer Monoclonal Antibodies Sales by Application (2015-2020) (K Units)
Table 54. Asia Pacific Cancer Monoclonal Antibodies Sales Market Share by Application (2015-2020)
Table 55. Latin America Cancer Monoclonal Antibodies Sales by Country (2015-2020) (K Units)
Table 56. Latin America Cancer Monoclonal Antibodies Sales Market Share by Country (2015-2020)
Table 57. Latin Americaa Cancer Monoclonal Antibodies Revenue by Country (2015-2020) (US$ Million)
Table 58. Latin America Cancer Monoclonal Antibodies Revenue Market Share by Country (2015-2020)
Table 59. Latin America Cancer Monoclonal Antibodies Sales by Type (2015-2020) (K Units)
Table 60. Latin America Cancer Monoclonal Antibodies Sales Market Share by Type (2015-2020)
Table 61. Latin America Cancer Monoclonal Antibodies Sales by Application (2015-2020) (K Units)
Table 62. Latin America Cancer Monoclonal Antibodies Sales Market Share by Application (2015-2020)
Table 63. Middle East and Africa Cancer Monoclonal Antibodies Sales by Country (2015-2020) (K Units)
Table 64. Middle East and Africa Cancer Monoclonal Antibodies Sales Market Share by Country (2015-2020)
Table 65. Middle East and Africa Cancer Monoclonal Antibodies Revenue by Country (2015-2020) (US$ Million)
Table 66. Middle East and Africa Cancer Monoclonal Antibodies Revenue Market Share by Country (2015-2020)
Table 67. Middle East and Africa Cancer Monoclonal Antibodies Sales by Type (2015-2020) (K Units)
Table 68. Middle East and Africa Cancer Monoclonal Antibodies Sales Market Share by Type (2015-2020)
Table 69. Middle East and Africa Cancer Monoclonal Antibodies Sales by Application (2015-2020) (K Units)
Table 70. Middle East and Africa Cancer Monoclonal Antibodies Sales Market Share by Application (2015-2020)
Table 71. F. Hoffmann-La Roche Corporation Information
Table 72. F. Hoffmann-La Roche Description and Major Businesses
Table 73. F. Hoffmann-La Roche Cancer Monoclonal Antibodies Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 74. F. Hoffmann-La Roche Product
Table 75. F. Hoffmann-La Roche Recent Development
Table 76. Amgen Corporation Information
Table 77. Amgen Description and Major Businesses
Table 78. Amgen Cancer Monoclonal Antibodies Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 79. Amgen Product
Table 80. Amgen Recent Development
Table 81. Bristol-Myers Squibb Corporation Information
Table 82. Bristol-Myers Squibb Description and Major Businesses
Table 83. Bristol-Myers Squibb Cancer Monoclonal Antibodies Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 84. Bristol-Myers Squibb Product
Table 85. Bristol-Myers Squibb Recent Development
Table 86. Takeda Pharmaceuticals Corporation Information
Table 87. Takeda Pharmaceuticals Description and Major Businesses
Table 88. Takeda Pharmaceuticals Cancer Monoclonal Antibodies Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 89. Takeda Pharmaceuticals Product
Table 90. Takeda Pharmaceuticals Recent Development
Table 91. Global Cancer Monoclonal Antibodies Sales Forecast by Regions (2021-2026) (K Units)
Table 92. Global Cancer Monoclonal Antibodies Sales Market Share Forecast by Regions (2021-2026)
Table 93. Global Cancer Monoclonal Antibodies Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 94. Global Cancer Monoclonal Antibodies Revenue Market Share Forecast by Regions (2021-2026)
Table 95. North America: Cancer Monoclonal Antibodies Sales Forecast by Country (2021-2026) (K Units)
Table 96. North America: Cancer Monoclonal Antibodies Revenue Forecast by Country (2021-2026) (US$ Million)
Table 97. Europe: Cancer Monoclonal Antibodies Sales Forecast by Country (2021-2026) (K Units)
Table 98. Europe: Cancer Monoclonal Antibodies Revenue Forecast by Country (2021-2026) (US$ Million)
Table 99. Asia Pacific: Cancer Monoclonal Antibodies Sales Forecast by Region (2021-2026) (K Units)
Table 100. Asia Pacific: Cancer Monoclonal Antibodies Revenue Forecast by Region (2021-2026) (US$ Million)
Table 101. Latin America: Cancer Monoclonal Antibodies Sales Forecast by Country (2021-2026) (K Units)
Table 102. Latin America: Cancer Monoclonal Antibodies Revenue Forecast by Country (2021-2026) (US$ Million)
Table 103. Middle East and Africa: Cancer Monoclonal Antibodies Sales Forecast by Country (2021-2026) (K Units)
Table 104. Middle East and Africa: Cancer Monoclonal Antibodies Revenue Forecast by Country (2021-2026) (US$ Million)
Table 105. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 106. Key Challenges
Table 107. Market Risks
Table 108. Main Points Interviewed from Key Cancer Monoclonal Antibodies Players
Table 109. Cancer Monoclonal Antibodies Customers List
Table 110. Cancer Monoclonal Antibodies Distributors List
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources
List of Figures
Figure 1. Cancer Monoclonal Antibodies Product Picture
Figure 2. Global Cancer Monoclonal Antibodies Sales Market Share by Type in 2020 & 2026
Figure 3. Murine Antibodies Product Picture
Figure 4. Chimeric and Humanised Antibodies Product Picture
Figure 5. Fully Humanized Antibodies Product Picture
Figure 6. Others Product Picture
Figure 7. Global Cancer Monoclonal Antibodies Sales Market Share by Application in 2020 & 2026
Figure 8. Liver
Figure 9. Breast
Figure 10. Blood
Figure 11. Brain
Figure 12. Hodgkins and Non-Hodgkins lymphoma
Figure 13. Colorectal
Figure 14. Leukaemia
Figure 15. Others
Figure 16. Cancer Monoclonal Antibodies Report Years Considered
Figure 17. Global Cancer Monoclonal Antibodies Market Size 2015-2026 (US$ Million)
Figure 18. Global Cancer Monoclonal Antibodies Sales 2015-2026 (K Units)
Figure 19. Global Cancer Monoclonal Antibodies Market Size Market Share by Region: 2020 Versus 2026
Figure 20. Global Cancer Monoclonal Antibodies Sales Market Share by Region (2015-2020)
Figure 21. Global Cancer Monoclonal Antibodies Sales Market Share by Region in 2019
Figure 22. Global Cancer Monoclonal Antibodies Revenue Market Share by Region (2015-2020)
Figure 23. Global Cancer Monoclonal Antibodies Revenue Market Share by Region in 2019
Figure 24. Global Cancer Monoclonal Antibodies Sales Share by Manufacturer in 2019
Figure 25. The Top 10 and 5 Players Market Share by Cancer Monoclonal Antibodies Revenue in 2019
Figure 26. Cancer Monoclonal Antibodies Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 27. Global Cancer Monoclonal Antibodies Sales Market Share by Type (2015-2020)
Figure 28. Global Cancer Monoclonal Antibodies Sales Market Share by Type in 2019
Figure 29. Global Cancer Monoclonal Antibodies Revenue Market Share by Type (2015-2020)
Figure 30. Global Cancer Monoclonal Antibodies Revenue Market Share by Type in 2019
Figure 31. Global Cancer Monoclonal Antibodies Market Share by Price Range (2015-2020)
Figure 32. Global Cancer Monoclonal Antibodies Sales Market Share by Application (2015-2020)
Figure 33. Global Cancer Monoclonal Antibodies Sales Market Share by Application in 2019
Figure 34. Global Cancer Monoclonal Antibodies Revenue Market Share by Application (2015-2020)
Figure 35. Global Cancer Monoclonal Antibodies Revenue Market Share by Application in 2019
Figure 36. North America Cancer Monoclonal Antibodies Sales Growth Rate 2015-2020 (K Units)
Figure 37. North America Cancer Monoclonal Antibodies Revenue Growth Rate 2015-2020 (US$ Million)
Figure 38. North America Cancer Monoclonal Antibodies Sales Market Share by Country in 2019
Figure 39. North America Cancer Monoclonal Antibodies Revenue Market Share by Country in 2019
Figure 40. U.S. Cancer Monoclonal Antibodies Sales Growth Rate (2015-2020) (K Units)
Figure 41. U.S. Cancer Monoclonal Antibodies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 42. Canada Cancer Monoclonal Antibodies Sales Growth Rate (2015-2020) (K Units)
Figure 43. Canada Cancer Monoclonal Antibodies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 44. North America Cancer Monoclonal Antibodies Market Share by Type in 2019
Figure 45. North America Cancer Monoclonal Antibodies Market Share by Application in 2019
Figure 46. Europe Cancer Monoclonal Antibodies Sales Growth Rate 2015-2020 (K Units)
Figure 47. Europe Cancer Monoclonal Antibodies Revenue Growth Rate 2015-2020 (US$ Million)
Figure 48. Europe Cancer Monoclonal Antibodies Sales Market Share by Country in 2019
Figure 49. Europe Cancer Monoclonal Antibodies Revenue Market Share by Country in 2019
Figure 50. Germany Cancer Monoclonal Antibodies Sales Growth Rate (2015-2020) (K Units)
Figure 51. Germany Cancer Monoclonal Antibodies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. France Cancer Monoclonal Antibodies Sales Growth Rate (2015-2020) (K Units)
Figure 53. France Cancer Monoclonal Antibodies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. U.K. Cancer Monoclonal Antibodies Sales Growth Rate (2015-2020) (K Units)
Figure 55. U.K. Cancer Monoclonal Antibodies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 56. Italy Cancer Monoclonal Antibodies Sales Growth Rate (2015-2020) (K Units)
Figure 57. Italy Cancer Monoclonal Antibodies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 58. Russia Cancer Monoclonal Antibodies Sales Growth Rate (2015-2020) (K Units)
Figure 59. Russia Cancer Monoclonal Antibodies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 60. Europe Cancer Monoclonal Antibodies Market Share by Type in 2019
Figure 61. Europe Cancer Monoclonal Antibodies Market Share by Application in 2019
Figure 62. Asia Pacific Cancer Monoclonal Antibodies Sales Growth Rate 2015-2020 (K Units)
Figure 63. Asia Pacific Cancer Monoclonal Antibodies Revenue Growth Rate 2015-2020 (US$ Million)
Figure 64. Asia Pacific Cancer Monoclonal Antibodies Sales Market Share by Region in 2019
Figure 65. Asia Pacific Cancer Monoclonal Antibodies Revenue Market Share by Region in 2019
Figure 66. China Cancer Monoclonal Antibodies Sales Growth Rate (2015-2020) (K Units)
Figure 67. China Cancer Monoclonal Antibodies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. Japan Cancer Monoclonal Antibodies Sales Growth Rate (2015-2020) (K Units)
Figure 69. Japan Cancer Monoclonal Antibodies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. South Korea Cancer Monoclonal Antibodies Sales Growth Rate (2015-2020) (K Units)
Figure 71. South Korea Cancer Monoclonal Antibodies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. India Cancer Monoclonal Antibodies Sales Growth Rate (2015-2020) (K Units)
Figure 73. India Cancer Monoclonal Antibodies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Australia Cancer Monoclonal Antibodies Sales Growth Rate (2015-2020) (K Units)
Figure 75. Australia Cancer Monoclonal Antibodies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Taiwan Cancer Monoclonal Antibodies Sales Growth Rate (2015-2020) (K Units)
Figure 77. Taiwan Cancer Monoclonal Antibodies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Indonesia Cancer Monoclonal Antibodies Sales Growth Rate (2015-2020) (K Units)
Figure 79. Indonesia Cancer Monoclonal Antibodies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Thailand Cancer Monoclonal Antibodies Sales Growth Rate (2015-2020) (K Units)
Figure 81. Thailand Cancer Monoclonal Antibodies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Malaysia Cancer Monoclonal Antibodies Sales Growth Rate (2015-2020) (K Units)
Figure 83. Malaysia Cancer Monoclonal Antibodies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 84. Philippines Cancer Monoclonal Antibodies Sales Growth Rate (2015-2020) (K Units)
Figure 85. Philippines Cancer Monoclonal Antibodies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 86. Vietnam Cancer Monoclonal Antibodies Sales Growth Rate (2015-2020) (K Units)
Figure 87. Vietnam Cancer Monoclonal Antibodies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 88. Asia Pacific Cancer Monoclonal Antibodies Market Share by Type in 2019
Figure 89. Asia Pacific Cancer Monoclonal Antibodies Market Share by Application in 2019
Figure 90. Latin America Cancer Monoclonal Antibodies Sales Growth Rate 2015-2020 (K Units)
Figure 91. Latin America Cancer Monoclonal Antibodies Revenue Growth Rate 2015-2020 (US$ Million)
Figure 92. Latin America Cancer Monoclonal Antibodies Sales Market Share by Country in 2019
Figure 93. Latin America Cancer Monoclonal Antibodies Revenue Market Share by Country in 2019
Figure 94. Mexico Cancer Monoclonal Antibodies Sales Growth Rate (2015-2020) (K Units)
Figure 95. Mexico Cancer Monoclonal Antibodies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 96. Brazil Cancer Monoclonal Antibodies Sales Growth Rate (2015-2020) (K Units)
Figure 97. Brazil Cancer Monoclonal Antibodies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 98. Argentina Cancer Monoclonal Antibodies Sales Growth Rate (2015-2020) (K Units)
Figure 99. Argentina Cancer Monoclonal Antibodies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 100. Latin America Cancer Monoclonal Antibodies Market Share by Type in 2019
Figure 101. Latin America Cancer Monoclonal Antibodies Market Share by Application in 2019
Figure 102. Middle East and Africa Cancer Monoclonal Antibodies Sales Growth Rate 2015-2020 (K Units)
Figure 103. Middle East and Africa Cancer Monoclonal Antibodies Revenue Growth Rate 2015-2020 (US$ Million)
Figure 104. Middle East and Africa Cancer Monoclonal Antibodies Sales Market Share by Country in 2019
Figure 105. Middle East and Africa Cancer Monoclonal Antibodies Revenue Market Share by Country in 2019
Figure 106. Turkey Cancer Monoclonal Antibodies Sales Growth Rate (2015-2020) (K Units)
Figure 107. Turkey Cancer Monoclonal Antibodies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 108. Saudi Arabia Cancer Monoclonal Antibodies Sales Growth Rate (2015-2020) (K Units)
Figure 109. Saudi Arabia Cancer Monoclonal Antibodies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 110. U.A.E Cancer Monoclonal Antibodies Sales Growth Rate (2015-2020) (K Units)
Figure 111. U.A.E Cancer Monoclonal Antibodies Revenue Growth Rate (2015-2020) (US$ Million)
Figure 112. Middle East and Africa Cancer Monoclonal Antibodies Market Share by Type in 2019
Figure 113. Middle East and Africa Cancer Monoclonal Antibodies Market Share by Application in 2019
Figure 114. North America Cancer Monoclonal Antibodies Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 115. North America Cancer Monoclonal Antibodies Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 116. Europe Cancer Monoclonal Antibodies Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 117. Europe Cancer Monoclonal Antibodies Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 118. Asia Pacific Cancer Monoclonal Antibodies Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 119. Asia Pacific Cancer Monoclonal Antibodies Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 120. Latin America Cancer Monoclonal Antibodies Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 121. Latin America Cancer Monoclonal Antibodies Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 122. Middle East and Africa Cancer Monoclonal Antibodies Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 123. Middle East and Africa Cancer Monoclonal Antibodies Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 124. Porter's Five Forces Analysis
Figure 125. Channels of Distribution
Figure 126. Distributors Profiles
Figure 127. Bottom-up and Top-down Approaches for This Report
Figure 128. Data Triangulation
Figure 129. Key Executives Interviewed
乳癌モノクローナル抗体の世界市場（～2026年） Breast cancer is characterized by the malignancy of cells in the tissues of the breast. HER-2 breast cancer is the most common type of breast cancer. The HER-2 protein, present on the surface of normal breast cells, affects the growth of the malignant cells. The uncontrolled synthesis of this protei…- モノクローナル抗体(mAb)バイオシミラーの世界市場（～2026年） A biosimilar medicine is a medicinal product of biological origin that is produced in a living organism following a procedure equivalent to a biological drug and adhering to the same quality criteria, hence the name biosimilars. In short, they are biological drugs that are “equivalent” in terms of q…
- 診断用特殊抗体の世界市場（～2026年） Market Analysis and Insights: Global Diagnostic Specialty Antibodies Market The global Diagnostic Specialty Antibodies market size is projected to reach US$ 20750 million by 2026, from US$ 20090 million in 2020, at a CAGR of 3.0%% during 2021-2026. Global Diagnostic Specialty Antibodies Scope and Ma…
- 治療用組換え抗体・タンパク質の世界市場（～2026年） Therapeutic proteins are engineered in the laboratory for pharmaceutical use, including non-covalent binders. These proteins are highly effective and serve as modernized treatment for rare as well as chronic diseases. Protein therapeutics offer custom-made treatment approach by supporting a specific…
- HER2抗体の世界市場（～2026年） The demand of HER2 Antibodies is increasing, and primarily gaining from growing awareness regarding the prevalence of HER2 positive breast cancer. Market Analysis and Insights: Global HER2 Antibodies Market The global HER2 Antibodies market size is projected to reach US$ 8543.4 million by 2026, from…